TIDMOXB

RNS Number : 5084H

Oxford Biomedica PLC

16 March 2015

Oxford BioMedica plc Director's Share Purchase

Oxford, UK - 16 March 2015: Oxford BioMedica plc ("Oxford BioMedica" or "the Company") (LSE: OXB), a leading gene and cell therapy company, was informed that on 13 March 2015 one of its Directors acquired ordinary shares of 1p each ("Ordinary Shares") as follows:

 
                                                          Interest after 
                                                           purchase 
-----------  -------------  ----------  ----------------  ---------------------------- 
 Director        Title        Price        Number of         Number       % of total 
   / PDMR                    per share   Ordinary Shares   of Ordinary      issued 
                                (p)        acquired on       Shares      share capital 
                                           25 November 
                                              2014 
-----------  -------------  ----------  ----------------  ------------  -------------- 
                 Chief 
              Development 
Paul Blake      Officer       10.25p         97,560        2,624,559        0.10% 
-----------  -------------  ----------  ----------------  ------------  --------------

The issued share capital of the Company is 2,567,098,228 1p ordinary shares.

-Ends-

 
 For further information, please 
  contact: 
 
   Oxford BioMedica plc: 
   John Dawson, Chief Executive Officer        Tel: +44 (0)1865 
   Tim Watts, Chief Financial Officer          783 000 
 
   Media Enquiries: 
   Mary-Jane Elliott/Emma Thompson/Matthew     Tel: +44 (0)20 
   Neal/Laura Thornton                         7309 5700 
   Consilium Strategic Communications

Notes for editors

About Oxford BioMedica(R)

Oxford BioMedica plc (LSE: OXB) is a leading gene and cell therapy company with an unrivalled portfolio of gene therapy products in development and a platform of exclusive and pioneering technologies with which it designs, develops and manufactures unique gene-based medicines for some of world's largest pharmaceutical companies. Leveraging its proprietary LentiVector(R) IP and gene delivery system technology platform and unique tumour antigen (5T4), Oxford BioMedica is advancing its pipeline of seven gene therapy products addressing diseases for which there are currently no treatments or that are inadequately treated today, including ocular and central nervous system disorders. OXB Solutions, the Company's industry-leading manufacturing and development business, provides services to collaborators and partners working in gene and cell therapy, including Novartis and Immune Design Corp. In addition, the Company has licenced products and IP to Sanofi, Pfizer, MolMed, Sigma-Aldrich, Biogen Idec, Emergent BioSolutions and ImaginAb. Further information is available at www.oxfordbiomedica.co.uk and www.oxbsolutions.co.uk.

This information is provided by RNS

The company news service from the London Stock Exchange

END

RDSGIGDXUUBBGUL

Oxford Biomedica (LSE:OXB)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Oxford Biomedica Charts.
Oxford Biomedica (LSE:OXB)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Oxford Biomedica Charts.